BDBM164901 US10166239, Ex. 3-15::US11406644, Example 3-15::US9067914, Ex. 3-15

SMILES COc1ccc(COc2ccc(Cn3c(N)nc4cc(cnc34)-c3cnn(C)c3)cc2OC)cc1

InChI Key InChIKey=HVRWZFQFSQUILC-UHFFFAOYSA-N

Data  16 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 164901   

TargetNT-3 growth factor receptor(Human)
Genzyme

US Patent
LigandPNGBDBM164901(US10166239, Ex. 3-15 | US11406644, Example 3-15 | ...)
Affinity DataIC50:  0.503nMAssay Description:Human TrkC, catalytic domain [456-825(end) amino acids of accession number NP-002521.2] was expressed as N-terminal GST-fusion protein (69 kDa) using...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetNT-3 growth factor receptor(Human)
Genzyme

US Patent
LigandPNGBDBM164901(US10166239, Ex. 3-15 | US11406644, Example 3-15 | ...)
Affinity DataIC50:  0.503nMAssay Description:Human TrkC, catalytic domain [456-825(end) amino acids of accession number NP_002521.2] was expressed as N-terminal GST-fusion protein (69 kDa) using...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetNT-3 growth factor receptor(Human)
Genzyme

US Patent
LigandPNGBDBM164901(US10166239, Ex. 3-15 | US11406644, Example 3-15 | ...)
Affinity DataIC50:  0.503nMAssay Description:Human TrkC, catalytic domain [456-825(end) amino acids of accession number NP_002521.2] was expressed as N-terminal GST-fusion protein (69 kDa) using...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetNT-3 growth factor receptor(Human)
Genzyme

US Patent
LigandPNGBDBM164901(US10166239, Ex. 3-15 | US11406644, Example 3-15 | ...)
Affinity DataIC50:  0.503nMAssay Description:Human TrkC, catalytic domain [456-825 (end) amino acids of accession number NP_002521.2] was expressed as N-terminal GST-fusion protein (69 kDa) usin...More data for this Ligand-Target Pair
In DepthDetails US Patent